Celldex Therapeutics Inc CLDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLDX is a good fit for your portfolio.
News
-
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
-
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
-
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
-
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
-
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
-
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
-
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Trading Information
- Previous Close Price
- $39.63
- Day Range
- $38.29–39.94
- 52-Week Range
- $22.11–53.18
- Bid/Ask
- $38.00 / $39.59
- Market Cap
- $2.53 Bil
- Volume/Avg
- 575,466 / 975,749
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 275.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 160
- Website
- https://www.celldex.com
Comparables
Valuation
|
Metric
|
CLDX
|
TYRA
|
ANAB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.10 | 3.09 | 6.48 |
Price/Sales | 275.86 | — | 33.69 |
Price/Cash Flow | — | — | — |
Price/Earnings
CLDX
TYRA
ANAB
Financial Strength
|
Metric
|
CLDX
|
TYRA
|
ANAB
|
|---|---|---|---|
Quick Ratio | 13.69 | 13.27 | 10.62 |
Current Ratio | 13.87 | 13.80 | 10.87 |
Interest Coverage | — | — | −9.09 |
Quick Ratio
CLDX
TYRA
ANAB
Profitability
|
Metric
|
CLDX
|
TYRA
|
ANAB
|
|---|---|---|---|
Return on Assets (Normalized) | −30.49% | −22.50% | −23.50% |
Return on Equity (Normalized) | −33.19% | −23.73% | −75.96% |
Return on Invested Capital (Normalized) | −32.85% | −27.79% | −68.56% |
Return on Assets
CLDX
TYRA
ANAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rwsvjcvtl | Xcvlj | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qgwmjwzk | Hzwljz | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kyvzrskg | Klzrp | $98.9 Bil | |
MRNA
| Moderna Inc | Qcrjttsxr | Dqrh | $39.7 Bil | |
ARGX
| argenx SE ADR | Nhhyvhqy | Frdz | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Lttflxg | Ntqd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Scyrrth | Mkfmwj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kpgslxd | Dfxvvj | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vkcgwwpkxc | Rqfqrm | $12.3 Bil | |
INCY
| Incyte Corp | Rvlcwpssc | Xbdcvt | $11.8 Bil |